Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "stem cell" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-2 z 2
    Tytuł:
    Effects of Insulin and Embryonic Stem Cells loaded PLGA Nanoparticles on Pancreatic Beta TC Cells
    Autorzy:
    Yücel, Çiğdem
    Aktaş, Yeşim
    Değim, Zelihagül
    Yılmaz, Şükran
    Arsoy, Taibe
    Altıntaş, Levent
    Çokçalışkan, Can
    Sözmen, Mahmut
    Powiązania:
    https://bibliotekanauki.pl/articles/895523.pdf
    Data publikacji:
    2018-12-31
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    diabetes
    insulin
    embryonic stem cell
    PLGA nanoparticles
    pancreatic beta TC cell
    Opis:
    In The present study, the aims was to investigate and compare the effect of insulin and embryonic stem cells (ESC) loaded nanoparticle formulations (NPs) on pancreatic-beta-TC-cell regeneration. Characterization studies of NPs were performed. Permeability of insulin and the effect of ESC on pancreatic beta cells were investigated. by the determination of Insulin or glucose levels were determined and histologic investigations were also performed. ESC encapsulation efficiency was calculated by western blot analysis. The particle sizes of insulin and ESC-loaded-NPs were determined as 0.665±0.202 µm and 0.650 ±0.310 µm. The mean zeta potentials of insulin and ESC-loaded-NPs nanoparticles were found as 6.88±0.729 mV, 5.13±0.631 mV. The polydispersity index of insulin and ESC nanoparticles were 0.660±0.175, 0.620±0.205 respectively. Encapsulation efficiency of insulin and ESC-loaded-NPs were found to be 50±1.53% and 51%. Insulin release from nanoparticles was found to be 72.8% over 48h. The gGlucose concentrations wasere decreased to 201 and 202.7 mg/dl from 250 mg/dl in streptozocin (STZ) induced diabetic mice group after insulin and ESC-loaded-NPs administration. Insulin and ESC-loaded-NPs improved the blood insulin levels in all experimental groups. These NPs may be used for repairing of pancreatic cells. Healing or some degree of regeneration was observed when insulin and ESC-loaded-NPs were administered to the mice ip. ESC-loaded-NPs can be a potential source for cell replacement therapy in the treatment of diabetes.
    Źródło:
    Acta Poloniae Pharmaceutica - Drug Research; 2018, 75, 6; 1377-1389
    0001-6837
    2353-5288
    Pojawia się w:
    Acta Poloniae Pharmaceutica - Drug Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    ANALYSIS OF CHRONIC MYELOID LEUKEMIA PHARMACOTHERAPY COSTS IN POLAND
    Autorzy:
    Paczkowska, Anna
    Kus, Krzysztof
    Nowicka, Monika
    Kopciuch, Dorota
    Zaprutko, Tomasz
    Komarnicki, Mieczysław
    Nowakowska, Elżbieta
    Powiązania:
    https://bibliotekanauki.pl/articles/895298.pdf
    Data publikacji:
    2019-02-28
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    poland
    chronic myeloid leukemia
    stem cell transplantation
    pharmacotherapy cost analysis
    Opis:
    The aim of this study was to analyze pharmacotherapy cost of chronic myeloid leukemia from the society’s, the payer’s (National Health Fund), and the patient’s perspective. The study included 55 patients with a diagnosed and treated chronic myeloid leukemia at the selected hematology clinic in the city of Poznan. Retrospective study involved time horizon of one calendar year – 2013. The data required for economic evaluation were obtained from the patients’ case histories and the Department of Organization and Accounting of the selected health care facilities. The total cost of chronic myeloid leukemia pharmacotherapy for 55 patients from the society’s perspective in 2013 amounted to 1,483,416.88 EUR. Average annual cost of medication per patient in 2013 amounted to 26,971.22 EUR (Median – 32,854.22 EUR). Average cost of chronic myeloid leukemia pharmacotherapy for a patient without transplantation was 32,167.34 EUR (Median – 30,623.00 EUR), and for a patient after transplantation amounted to 413.13 EUR (Median – 378.40 EUR). The cost from the payer’s perspective is 99.93% of total costs from the society’s perspective. The cost from the patient’s perspective represents 0.07% of the total cost of chronic myeloid leukemia pharmacotherapy from the society’s perspective. Costs of chronic myeloid leukemia pharmacotherapy are very high and represent a significant burden to society. The highest costs associated with treatment of chronic myeloid leukemia are incurred by the society, and, subsequently, the public payer (NHF), and the patient.
    Źródło:
    Acta Poloniae Pharmaceutica - Drug Research; 2019, 76, 1; 175-183
    0001-6837
    2353-5288
    Pojawia się w:
    Acta Poloniae Pharmaceutica - Drug Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-2 z 2

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies